Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024

This “Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Proto-oncogene protein c mdm2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Proto-oncogene protein c mdm2 inhibitors Understanding

Proto-oncogene protein c mdm2 inhibitors: Overview

The MDM2 oncoprotein has been validated as a potential target for cancer drug development. MDM2 amplification and/or overexpression occur in a wide variety of human cancers, several of which can be treated experimentally with MDM2 antagonists. MDM2 interacts primarily with the p53 tumor suppressor protein in an autoregulatory negative feedback loop to attenuate p53's cell cycle arrest and apoptosis functions. Inhibition of the p53-MDM2 interaction has been shown to cause selective cancer cell death, as well as sensitize cancer cells to chemotherapy or radiation effects. Consequently, this interaction has been the main focus of anticancer drug discovery targeted to MDM2. The promotion of the proteasomal degradation of the p53 protein by MDM2 is central to its repression of the tumor suppressor functions of p53, and many proteins impinge upon this activity, either enhancing or inhibiting it. MDM2 also has oncogenic activity independent of its interaction with p53, but this has so far not been explored for drug discovery. Among the approaches for targeting MDM2 for cancer therapy, small molecule antagonists have recently featured as effective anticancer agents.

Proto-oncogene protein c mdm2 inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proto-oncogene protein c mdm2 inhibitors pipeline landscape is provided which includes the disease overview and Proto-oncogene protein c mdm2 inhibitors treatment guidelines. The assessment part of the report embraces, in depth Proto-oncogene protein c mdm2 inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proto-oncogene protein c mdm2 inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proto-oncogene protein c mdm2 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Proto-oncogene protein c mdm2 inhibitors.

Proto-oncogene protein c mdm2 inhibitors Emerging Drugs Chapters

This segment of the Proto-oncogene protein c mdm2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Proto-oncogene protein c mdm2 inhibitors Emerging Drugs

Milademetan: Rain Therapeutics RAIN-32 has been evaluated in patients with various solid tumors, acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). RAIN-32 also has been evaluated in continuous and intermittent dose schedules that may offer a differentiated tolerability profile as compared to other MDM2 programs. Two clinical studies for RAIN-32 are ongoing, including a study evaluating the safety and efficacy of RAIN-32 in patients with liposarcoma and in patients with FLT3-ITD AML treated with RAIN-32 and the FLT3 inhibitor, quizartinib. In addition, multiple investigator sponsored studies are being conducted by MD Anderson Cancer Center (MDACC) as well as National Cancer Center Hospital (NCCH) in Tokyo, Japan. In September 2020, worldwide rights were out-licensed from Daiichi-Sankyo to Rain Therapeutics, a privately held, clinical-stage biotech company focused on targeted therapies in oncology, who renamed the product RAIN-32. In April 2021, Rain announced a planned Phase III study for the asset in liposarcoma, a cancer that occurs in the body’s fat cells, to start in H2 2021.

Navtemadlin: Kartos Therapeutics KARTOS THERAPEUTICS is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor (KRT-232). Navtemadlin (KRT-232) is an investigational oral small molecule designed as a potent and selective inhibitor of the MDM2-p53 interaction. MDM2 inhibition permits p53 to be activated and exert its tumor suppressor functions. Preclinical data support the investigation of navtemadlin (KRT-232) for its potential therapeutic utility for treating certain types of cancers where MDM2 is overly active. It is currently being evaluated in Phase II/III stage of development for the treatment of Myelofibrosis and in other stages for the treatment of other potential indications.

Proto-oncogene protein c mdm2 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto-oncogene protein c mdm2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Proto-oncogene protein c mdm2 inhibitors

There are approx. 5+ key companies which are developing the therapies for Proto-oncogene protein c mdm2 inhibitors. The companies which have their Proto-oncogene protein c mdm2 inhibitors drug candidates in the most advanced stage, i.e. phase III include Rain therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Proto-oncogene protein c mdm2 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proto-oncogene protein c mdm2 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proto-oncogene protein c mdm2 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto-oncogene protein c mdm2 inhibitors drugs.

Proto-oncogene protein c mdm2 inhibitors Report Insights

• Proto-oncogene protein c mdm2 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Proto-oncogene protein c mdm2 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Proto-oncogene protein c mdm2 inhibitors drugs?
• How many Proto-oncogene protein c mdm2 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto-oncogene protein c mdm2 inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proto-oncogene protein c mdm2 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Proto-oncogene protein c mdm2 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.